We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Fig. 1 · Structure
Cat. No.
A10941
CAS No.
56211-40-6
Formula
C16H20N4O3S
Mol. Weight
348.42

Documents & Downloads

Torsemide

Diuretic

Torsemide is an orally active loop diuretic that primarily targets the renal system to promote diuresis. It exhibits anti-aldosterone properties and vasodilatory effects, making it valuable in the study of cardiovascular and renal pathologies. Torsemide is commonly utilized in research related to heart failure, renal disease, and hepatic cirrhosis.

In Stock

Notify me when the price drops

For laboratory research use only. We do not sell to patients.

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vitro Studies

In COS-7 cells expressing the functional fluorescent MR-147-GFP variant, Torsemide alone without aldosterone produced no detectable MR-GFP translocation. In H9C2-MR cells, Torsemide alone significantly decreased basal expression of Orosomucoid-1 and Tenascin-X in the absence of serum and aldosterone. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Torsemide and MR Localization in Transfected Cells

Cell-based study · COS-7 cells transiently transfected with the previously described MR-147-GFP functional fluorescent variant of MR [1]

In cells treated with 10−6 M torasemide alone (without aldosterone) no translocation of the MR-GFP was detected.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
average percentage fluorescent intensity of the nucleus vs. total cellular fluorescence (Fn/Ft)Reported result In cells treated with 10−6 M torasemide alone (without aldosterone) no translocation of the MR-GFP was detected.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10−6 M
Exposure duration
images were acquired every 2 minutes (min) for one hour
Method
Cells were treated
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Torsemide; Compound label in the paper: Torasemide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Ligand-induced MR Nuclear Translocation Assay (S7); Results > Effect of Torasemide on MR Translocation into the Nucleus (S34, S37); Figure 1 legend (S63)

average percentage fluorescent intensity of the nucleus vs. total cellular fluorescence (Fn/Ft): average percentage fluorescent intensity of the nucleus vs. total cellular fluorescence (Fn/Ft); comparator: Cells were treated or not — Results > Effect of Torasemide on MR Translocation into the Nucleus (S37); Figure 1 legend (S63)

Basal gene expression following treatment

Cell-based study · H9C2-MR cells [1]

H9C2-MR cells were treated with Torsemide alone. Treatment significantly decreased basal expression of Orosomucoid-1 and Tenascin-X in the absence of serum and aldosterone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
basal expression (in absence of serum and aldosterone) of Orosomucoid-1 and Tenascin-XReported result Torasemide (10−6 M) alone significantly decreased the basal expression (in absence of serum and aldosterone) of Orosomucoid-1 and Tenascin-X[1]

Literature-Reported Treatment Conditions

Treatment concentration
10−6 M
Method
H9C2-MR cells were treated
Reported limits
Not stated in the sentences used: schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Torsemide; Compound label in the paper: Torasemide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Gene Expression in H9C2-MR Cells (S18); Results > Effect of Torasemide on MR-mediated Endogenous Gene Expression in H9C2-MR Cells (S52, S54)

basal expression (in absence of serum and aldosterone) of Orosomucoid-1 and Tenascin-X: basal expression (in absence of serum and aldosterone) of Orosomucoid-1 and Tenascin-X — Results > Effect of Torasemide on MR-mediated Endogenous Gene Expression in H9C2-MR Cells (S54)

Specifications

Manufacturer Adooq Bioscience
CAS Number 56211-40-6
Applications Diuretic
Formula C16H20N4O3S
Molecular Weight 348.42
Synonyms Torasemide
SMILES
O=S(C1=C(NC2=CC=CC(C)=C2)C=CN=C1)(NC(NC(C)C)=O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Gravez B, Tarjus A, Jimenez-Canino R, et al. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes. PLoS One (2013). PMID: 24040049 DOI: 10.1371/journal.pone.0073737 Source material

Added to your cart

View Cart Checkout
Loading...